Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Linagliptin and Pioglitazone Co-administration
NCT02183337Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2007
- Primary completion
- Apr 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state up to 21 days and Maximum measured concentration at steady state up to 21 days. Started Feb 2007; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183337.